Study To Know The Rifaximin Efficacy In Hepatic Encephalopathy Prevention In Cirrhosis Of Liver
Objective: To evaluate the safety and efficacy of Rifaximin in patients with liver cirrhosis to prevent hepatic encephalopathy recurrence according to lactulose alone. Study design: Randomized controlled trial. Location and duration: In the Gastroenterology department of Bahawal Victoria Hospital, Bahawalpur for the Period of one year from May 2016 to May 2017. Methodology: We had hepatic encephalopathy reports for approximately 4 weeks of liver cirrhosis to randomly receive selected rifaximin.
... selected rifaximin. 550 mg twice daily dose in 196 patients received (99 patient) or only lactulose (97 patients). They asked or found patients to take oral medication twice a day for 6 months until they experienced HE's recurrence. RESULTS: Hepatic encephalopathy reduces recurrence over a period of significant six months, when compared with lactulose alone. Hepatic encephalopathy was suddenly present in 19 (19.19%) of the patients taking rifaximin, compared with 49 (50.51%) patients in the lactulose group. Hepatic encephalopathy was admitted in 12.6% (8) of the patients in the rifaximin group and 23.8% (15) in the total lactulose group, compared to the disease. 79 patients (79.79%) in the rifaximin group and 48 patients (49.48%) in the lactulose group had hepatic encephalopathy during the study period. In the majority of patients with advanced HE, 21-25 was the MELD score was in both groups. In both groups Death rate and morbidity rate was same. Conclusion: Treatment with rifaximin at a 6-month period was more effective than lactulose alone in maintaining hepatic encephalopathy remission. In our study, rifaximin reduced hospitalization frequency significantly in patients with hepatic encephalopathy. Key words: Hepatic encephalopathy, Rifaximin, Liver cirrhosis.